Travis E Grotz
Overview
Explore the profile of Travis E Grotz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fackche N, Schmocker R, Nudotor R, Kubi B, Cloyd J, Grotz T, et al.
Ann Surg Oncol
. 2024 Feb;
31(5):3314-3324.
PMID: 38310181
Introduction: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this...
12.
Buckarma E, Thiels C, Jin Z, Grotz T
Ann Surg Oncol
. 2023 Oct;
31(1):622-629.
PMID: 37880514
Background: Peritoneal metastasis (PM) is the most common site of dissemination of gastric cancer (GC) and is associated with a poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)...
13.
Bhutiani N, Grotz T, Concors S, White M, Helmink B, Raghav K, et al.
Ann Surg Oncol
. 2023 Oct;
31(1):614-621.
PMID: 37872456
Introduction: Many patients with mucinous appendiceal adenocarcinoma experience peritoneal recurrence despite complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prior work has demonstrated that repeat CRS/HIPEC can prolong survival...
14.
Steadman J, Grotz T
J Natl Compr Canc Netw
. 2023 Sep;
21(9):981-986.
PMID: 37673112
Malignant peritoneal mesothelioma (MPeM) is a rare malignancy and represents 5% to 30% of malignant mesothelioma cases. The primary curative therapy for MPeM is radical cytoreductive surgery (CRS) and hyperthermic...
15.
Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2023 Sep;
21(9):961-979.
PMID: 37673108
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM)....
16.
SenthilKumar G, Merrill J, Maduekwe U, Cloyd J, Fournier K, Abbott D, et al.
J Surg Res
. 2023 Sep;
292:275-288.
PMID: 37666090
Introduction: In patients with disseminated appendiceal cancer (dAC) who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), characterizing and predicting those who will develop early recurrence could provide a...
17.
Kartik A, Muller C, Acs M, Piso P, Starlinger P, Bachleitner-Hofmann T, et al.
Pleura Peritoneum
. 2023 Sep;
8(3):113-121.
PMID: 37662605
Objectives: Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is associated with significant postoperative complications. Early detection of at-risk patients may lead to improved outcomes. The role of C-reactive protein...
18.
Winicki N, Radomski S, Florissi I, Cloyd J, Gutta G, Grotz T, et al.
Ann Surg Oncol
. 2023 Aug;
30(12):7840-7847.
PMID: 37620532
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) improves survival in select patients with peritoneal metastases (PM), but the impact of social determinants of health on CRS/HIPEC outcomes remains unclear....
19.
Gudmundsdottir H, Yonkus J, Thiels C, Warner S, Cleary S, Kendrick M, et al.
Ann Surg Oncol
. 2023 Aug;
30(12):7833-7839.
PMID: 37596449
Background: Peritoneal metastases (PM) from pancreatic ductal adenocarcinoma (PDAC) are currently treated with palliative systemic chemotherapy alone, with unsatisfactory results. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may provide...
20.
SenthilKumar G, Kothari A, Maduekwe U, Fournier K, Abbott D, Wilson G, et al.
Ann Surg Oncol
. 2023 Jun;
30(9):5743-5753.
PMID: 37294386
Background: The AJCC 8th edition stratifies stage IV disseminated appendiceal cancer (dAC) patients based on grade and pathology. This study was designed to externally validate the staging system and to...